PDCD1 and neoplasm: Especially anti-VEGFR2, which inhibits tumor neovascularization and PD-1 blockade, enhanced the local immunity, including IFN-γ and TNF-α expression [69].The bispecific antibody (A2V), which blocks angiopoietin-2(ANGPT2) and VEGFA, provides anti-tumor benefits in metastatic breast cancer, pancreatic neuroendocrine tumors and melanoma, including the promotion of vascular regression, normalizing the remaining blood vessels and facilitating the perivascular accumulation of activated CD8+ cytotoxic T lymphocyte (CTL) infiltration.